Skip to main content
OpenTrials
Completed

NCT Number: NCT05832476

O-GlcNac Modified Proteomics Study of the Maturation of Hemodialysis Arteriovenous

We divided into three parts to carry out. Firstly, evidence the pre-existing fibrosis in vein of AVF failure patients. investigation of expression, the role, and the mechanism by which the identified O-GlcNAac proteins promote, maturation of AV fistula. Finally, ddress and compare the proteomics differentiation between failure and maturation of AVF patients.

Completed

Looking for future studies?

Notify Me

Key information

About this study

End stage renal disease (ESRD) patients requires hemodialysis to maintain bloodstream functions. Before the hemodialysis, the patients requires a long-term vascular access, which best choice is Arteriovenous fistulas (AVF). However, 1/3 of patients were failure in AVF maturation, and it is still unknown. Our preliminary data have shown that pre-exisiting fibrosis in vein of AVF failure. Here, we will investigate whether pre-existing fibrosis of vein is asssociated with circulating fibrocytes in AVF failure, and further to address molecular mechanism of fibrocytes differentiation. We will divide into three parts to carry out. Firstly, evidence the pre-existing fibrosis in vein of AVF failure patients. Secondary, investigation of expression, the role, and the mechanism by which the identified O-GlcNAac proteins promote, maturation of AV fistula. Finally, address and compare the proteomics differentiation between failure and maturation of AVF patients. We hope that through this project, we can obtain signifiture molecules for precision detection and solve the current clinical unmet need.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age of 20 and older adult patients, and preoperatively clinical and ultrasound assessment of the arm vessels are fisible for the creation of a native HDAVF that include:the augmented diameters of the veins is > 2.0 mm and the diameter of the radial artery is> 2.0 mm. Besides, there is no obvious stenosis of vessels in the forearm.

Exclusion criteria

  • The patient refused to join the study
  • Too weak
  • Serious heart failure
  • Unconsciousness
  • Bedridden for long time
  • systemic lupus erythematosus(SLE), or other known autoimmune diseases
  • The physician excludes the possibility of creating a wrist HDAVF before surgery
  • Surgeon preoperatively identifies vessel inadequacy for the creation of a wrist HDAVF
  • Choose a site other than the wrist for surgery
  • Unexpected negative complications happen during surgery that prevent the completion of a wirst HDAVF

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

  1. The diameter of each passage of the passage vein (forearm head vein) of the arterial and venous access within three months

    Time frame: Postoperative Three months

    Comparison of the various methods to achieve within three months the checkpoint path diameter increase rate (two time points measurement difference).

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Apr 27, 2023
Registry last updated
Apr 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.